Welcome!

News Feed Item

Lombard Medical Technologies PLC: Pre-Close Trading and Strategic Update

LONDON, UK -- (Marketwired) -- 01/08/14 --

                   Lombard Medical Technologies PLC
                 ("Lombard Medical" or "the Company")

                Pre-Close Trading and Strategic Update

         Global AorfixTM growth; US rollout progressing well
  Intention to pursue a US IPO and NASDAQ listing of ordinary shares

London, UK and Irvine, CA, 8 January, 2014 - Lombard Medical
Technologies PLC (AIM: LMT), the specialist medical device company
focused on Endovascular Aortic Repair ("EVAR") of abdominal aortic
aneurysms ("AAAs"), announced today a pre-close trading update for the
financial year ended 31 December 2013 as well as a strategic update.
All figures are unaudited.

Trading Update

AorfixTM commercial revenue grew 25% to GBP3.9m with revenue from the
main EU markets growing 9%. Revenue from the Rest of World ("ROW")
markets grew 28% and the US contributed to fourth quarter Aorfix
commercial revenue growth of 38% following formal launch in November.
In Europe, the Company experienced strong demand and revenue growth in
Germany and Spain. Following consolidation of EVAR centers in the UK,
which negatively impacted UK revenue in the first half of 2013, second
half 2013 Aorfix revenue in the UK recovered and was flat compared to
the same period the previous year. Total Company revenue grew by 14% to
GBP4.5m, reflecting a decline in revenue of the recently divested OEM
business in Scotland which fell by 27% compared to last year. As
previously announced, this business was divested on 20 December 2013.

Aorfix was approved by the United States Food and Drug Administration
("US FDA") in February 2013 with a unique label indication for the
treatment of patients with angulations at the neck of the aneurysm up
to and including 90 degrees. The product was formally launched in the
US, the largest EVAR market, at the 40th Annual VEITH Symposium, in New
York in November. While Aorfix is still in the initial phase of the US
launch, the product rollout is progressing well, with the number of US
physicians trained to use the device standing at 244 at the year end.
As previously disclosed, the Company's 20-person sales team is
targeting around 300 high volume EVAR centers that perform more than
half of the EVAR procedures in the US.

In Japan, the Company now anticipates regulatory approval for Aorfix
during 2014. Our exclusive Japanese marketing partner, Medico's
Hirata, remains in dialogue with the Pharmaceuticals and Medical
Devices Agency (PMDA) to achieve this. Medico's Hirata is a leading
supplier of medical device products in Japan, with the sales
infrastructure to realize the potential of Aorfix in this growing
market, which in 2013 was estimated to account for approximately $140m
or 10% of the global EVAR market.

As previously announced, the Company is expanding its manufacturing
facility in Didcot, Oxfordshire, to support increasing global demand
for Aorfix. The expansion, which involves the construction of a new
cleanroom and materials handling space, will add around 10,000 sq. ft.
to the existing facility. The expansion project is expected to be
completed by the end of the first quarter of 2014.

The global AAA market for EVAR devices is estimated to be approximately
$1.4bn. The US market is estimated to be worth around half of the
global market and is expected to grow at a compound annual growth rate
in excess of 7% over the next 5 years, driven largely by the growth of
the ageing population and patient screening programs. In addition,
introduction of new technologies such as Aorfix, which allow more
patients to received endovascular treatment of AAA disease, could
potentially further expand the market.

The Company closed 2013 with cash of GBP24.8m and debt of GBP1.5m on its
balance sheet.

NASDAQ IPO

As announced today in a separate press release, the Company intends to
submit a registration statement to the US Securities and Exchange
Commission ("SEC") relating to a proposed US initial public offering of
ordinary shares and a listing on NASDAQ ("NASDAQ IPO").

To facilitate the NASDAQ IPO, a new Cayman Islands holding company will
be created and existing shares in Lombard Medical will be exchanged for
new shares in that holding company ("Share Exchange")

Commencement of the initial public offering is conditional upon
completion of the SEC review process with respect to the registration
statement and is subject to market conditions and other
considerations. In connection with the NASDAQ IPO, Lombard Medical
will also delist its ordinary shares from AIM, a market of the London
Stock Exchange.

In the Share Exchange, existing shareholders will receive shares in the
new Cayman Islands holding company in exchange for the shares they hold
in Lombard Medical. These new shares will not be admitted to trading on
AIM. Shareholders will need to consider their ability to hold and trade
NASDAQ listed shares following the Share Exchange and the AIM
delisting. Full details of the proposals will be set out in a circular
to shareholders in due course.

Lombard Medical intends to use proceeds from the NASDAQ IPO to
accelerate its commercialization strategy for Aorfix in the US with a
particular focus on continuing to expand its direct sales force to
accelerate penetration of the US AAA market. The Company will also
continue to invest in developing new products to treat complex vascular
disease, including a stent graft to treat aneurysms in the thoracic
aorta.

This press release does not constitute an offer of any securities for
sale.

                               -Ends-


For further information:

Lombard Medical Technologies PLC              Tel: +44 (0)1235 750 800
Simon Hubbert, Chief Executive Officer
Ian Ardill, Chief Financial Officer

Canaccord Genuity Limited                     Tel: +44 (0)20 7523 8000
Lucy Tilley / Tim Redfern /
Henry Fitzgerald O'Connor / Dr Julian Feneley

FTI Consulting (UK)                           Tel: +44 (0)20 7831 3113
Simon Conway / Stephanie Cuthbert /
Victoria Foster Mitchell

Allen & Caron (US)                            Tel: +1 (949) 474 4300
Matt Clawson


About Abdominal Aortic Aneurysms

AAAs are a balloon-like enlargement of the aorta which, if left
untreated, may rupture and cause death. Approximately 4.5 million
people are living with AAAs in the developed world and each year over
500,000 new cases are diagnosed. In the US, aortic aneurysm disease is
among the leading causes of death and it is estimated that 1.7 million
people over the age of 55 have an abdominal aortic aneurysm.

About Lombard Medical

Lombard Medical Technologies PLC (AIM: LMT) is a medical device company
focused on device solutions for the $1.4 billion per annum abdominal
aortic aneurysm ("AAA") repair market. The Company's lead product,
Aorfix, is an endovascular stent graft which has been specifically
designed to solve the problems that exist in treating complex tortuous
anatomy, which is often present in advanced AAA disease. Aorfix is the
only stent graft approved for AAA neck angulations of up to 90 degrees
and is currently being commercialized worldwide. Aorfix is the first
AAA stent graft not of US origin to gain US FDA approval. The Company
is headquartered in Oxfordshire, England with US operations in Irvine,
CA.

Further background on the Company can be found at
www.lombardmedical.com.

FORWARD-LOOKING STATEMENTS

This announcement may contain forward-looking statements that reflect
the Company's current expectations regarding future events, including
the commercialization and regulatory clearance of the Company's
products, the Group's liquidity and results of operations, as well as
the Group's future capital raising activities. Forward-looking
statements involve risks and uncertainties. Actual events could differ
materially from those projected herein and depend on a number of
factors, including the success of the Company's research and
development and commercialization strategies, the uncertainties related
to the regulatory process and the acceptance of the Company's products
by hospitals and other medical professionals.



                    This information is provided by RNS
          The company news service from the London Stock Exchange

END

Contacts:
RNS
Customer
Services
0044-207797-4400
Email Contact
http://www.rns.com

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
With more than 30 Kubernetes solutions in the marketplace, it's tempting to think Kubernetes and the vendor ecosystem has solved the problem of operationalizing containers at scale or of automatically managing the elasticity of the underlying infrastructure that these solutions need to be truly scalable. Far from it. There are at least six major pain points that companies experience when they try to deploy and run Kubernetes in their complex environments. In this presentation, the speaker will d...
While DevOps most critically and famously fosters collaboration, communication, and integration through cultural change, culture is more of an output than an input. In order to actively drive cultural evolution, organizations must make substantial organizational and process changes, and adopt new technologies, to encourage a DevOps culture. Moderated by Andi Mann, panelists discussed how to balance these three pillars of DevOps, where to focus attention (and resources), where organizations might...
The deluge of IoT sensor data collected from connected devices and the powerful AI required to make that data actionable are giving rise to a hybrid ecosystem in which cloud, on-prem and edge processes become interweaved. Attendees will learn how emerging composable infrastructure solutions deliver the adaptive architecture needed to manage this new data reality. Machine learning algorithms can better anticipate data storms and automate resources to support surges, including fully scalable GPU-c...
When building large, cloud-based applications that operate at a high scale, it's important to maintain a high availability and resilience to failures. In order to do that, you must be tolerant of failures, even in light of failures in other areas of your application. "Fly two mistakes high" is an old adage in the radio control airplane hobby. It means, fly high enough so that if you make a mistake, you can continue flying with room to still make mistakes. In his session at 18th Cloud Expo, Le...
Machine learning has taken residence at our cities' cores and now we can finally have "smart cities." Cities are a collection of buildings made to provide the structure and safety necessary for people to function, create and survive. Buildings are a pool of ever-changing performance data from large automated systems such as heating and cooling to the people that live and work within them. Through machine learning, buildings can optimize performance, reduce costs, and improve occupant comfort by ...
As Cybric's Chief Technology Officer, Mike D. Kail is responsible for the strategic vision and technical direction of the platform. Prior to founding Cybric, Mike was Yahoo's CIO and SVP of Infrastructure, where he led the IT and Data Center functions for the company. He has more than 24 years of IT Operations experience with a focus on highly-scalable architectures.
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
CI/CD is conceptually straightforward, yet often technically intricate to implement since it requires time and opportunities to develop intimate understanding on not only DevOps processes and operations, but likely product integrations with multiple platforms. This session intends to bridge the gap by offering an intense learning experience while witnessing the processes and operations to build from zero to a simple, yet functional CI/CD pipeline integrated with Jenkins, Github, Docker and Azure...
René Bostic is the Technical VP of the IBM Cloud Unit in North America. Enjoying her career with IBM during the modern millennial technological era, she is an expert in cloud computing, DevOps and emerging cloud technologies such as Blockchain. Her strengths and core competencies include a proven record of accomplishments in consensus building at all levels to assess, plan, and implement enterprise and cloud computing solutions. René is a member of the Society of Women Engineers (SWE) and a m...
Dhiraj Sehgal works in Delphix's product and solution organization. His focus has been DevOps, DataOps, private cloud and datacenters customers, technologies and products. He has wealth of experience in cloud focused and virtualized technologies ranging from compute, networking to storage. He has spoken at Cloud Expo for last 3 years now in New York and Santa Clara.
Enterprises are striving to become digital businesses for differentiated innovation and customer-centricity. Traditionally, they focused on digitizing processes and paper workflow. To be a disruptor and compete against new players, they need to gain insight into business data and innovate at scale. Cloud and cognitive technologies can help them leverage hidden data in SAP/ERP systems to fuel their businesses to accelerate digital transformation success.
Containers and Kubernetes allow for code portability across on-premise VMs, bare metal, or multiple cloud provider environments. Yet, despite this portability promise, developers may include configuration and application definitions that constrain or even eliminate application portability. In this session we'll describe best practices for "configuration as code" in a Kubernetes environment. We will demonstrate how a properly constructed containerized app can be deployed to both Amazon and Azure ...
Poor data quality and analytics drive down business value. In fact, Gartner estimated that the average financial impact of poor data quality on organizations is $9.7 million per year. But bad data is much more than a cost center. By eroding trust in information, analytics and the business decisions based on these, it is a serious impediment to digital transformation.
Digital Transformation: Preparing Cloud & IoT Security for the Age of Artificial Intelligence. As automation and artificial intelligence (AI) power solution development and delivery, many businesses need to build backend cloud capabilities. Well-poised organizations, marketing smart devices with AI and BlockChain capabilities prepare to refine compliance and regulatory capabilities in 2018. Volumes of health, financial, technical and privacy data, along with tightening compliance requirements by...
Predicting the future has never been more challenging - not because of the lack of data but because of the flood of ungoverned and risk laden information. Microsoft states that 2.5 exabytes of data are created every day. Expectations and reliance on data are being pushed to the limits, as demands around hybrid options continue to grow.